TuHURA Biosciences (NASDAQ:HURA) Coverage Initiated at HC Wainwright

Equities researchers at HC Wainwright started coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a report released on Monday. The brokerage set a “buy” rating and a $13.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 439.42% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Maxim Group assumed coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price target for the company. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Finally, Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock.

TuHURA Biosciences Price Performance

Shares of HURA stock opened at $2.41 on Monday. The business has a fifty day moving average price of $4.21. TuHURA Biosciences has a one year low of $2.31 and a one year high of $14.60.

Hedge Funds Weigh In On TuHURA Biosciences

Institutional investors have recently bought and sold shares of the business. Accent Capital Management LLC acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at $29,000. TT Capital Management LLC bought a new stake in TuHURA Biosciences during the 4th quarter worth about $41,000. Jefferies Financial Group Inc. acquired a new stake in TuHURA Biosciences in the 4th quarter valued at about $54,000. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences in the fourth quarter worth about $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of TuHURA Biosciences during the fourth quarter worth approximately $61,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.